MD
MDXG.US MiMedx Group Inc
- Market cap
- USD 468M
- P/E
- -
- P/B
- 2.22x
- ROE
- -21.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MDXG.US undervalued?
Graham numberThe Graham number of MiMedx Group Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MiMedx Group Inc fundamental analysis
No fundamental analysis for MiMedx Group Inc yet.
MiMedx Group Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MiMedx Group Inc
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs asep…
Full company profileMiMedx Group Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MiMedx Group Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 245M | 321M | 359M | 359M | 248M | 242M | 268M | 321M | 349M | 419M | 248M |
| Gross Profit | 213M | 286M | 323M | 323M | 209M | 202M | 220M | 267M | 289M | 346M | 181M |
| Operating Income | 884K | 46.2M | -3.92M | -3.92M | -45.4M | -7.05M | -14.7M | 37.1M | 58.9M | 63.9M | -61.6M |
| EBITDA | 8.93M | 52.6M | 2.99M | 17.6M | -37.5M | -1.89M | -10.7M | 40.5M | 65.4M | 82.9M | -53.3M |
| Net Income | 12.0M | 64.7M | -30.0M | -30.0M | -49.3M | -12.3M | -30.2M | 67.4M | 42.4M | 48.6M | -45.8M |
| EPS | 0.11 | 0.56 | -0.27 | -0.28 | -0.46 | -0.11 | -0.27 | 0.46 | 0.28 | 0.32 | -0.31 |
| Balance Sheet | |||||||||||
| Total Assets | 193M | 121M | 123M | 123M | 202M | 188M | 171M | 239M | 264M | 343M | 265M |
| Total Liabilities | 60.3M | 47.5M | 73.2M | 73.2M | 111M | 95.4M | 96.9M | 96.3M | 70.8M | 86.1M | 53.5M |
| Shareholders' Equity | 133M | 73.8M | 49.7M | 49.7M | 91.4M | 92.6M | 74.5M | 143M | 193M | 257M | 211M |
| Cash & Short-term Investments | 34.4M | 27.5M | 45.1M | 45.1M | 95.8M | 87.1M | 66.0M | 82.0M | 104M | 166M | 121M |
| Total Debt | 31.0K | 286K | - | 229K | 51.8M | 53.3M | 52.5M | 48.1M | 24.8M | 22.5M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 23.8M | 62.9M | 35.8M | 35.8M | -39.4M | -1.98M | -17.9M | 26.8M | 66.2M | 74.0M | -5.62M |
| Capital Expenditure | 6.21M | 5.13M | 9.42M | 9.42M | 2.22M | 3.22M | 2.68M | 1.99M | 1.68M | 1.03M | 3.41M |
| Free Cash Flow | 17.6M | 57.8M | 26.4M | 26.4M | -41.6M | -5.20M | -20.6M | 24.8M | 64.5M | 73.0M | -5.62M |
| Ratios | |||||||||||
| ROE | 9.0% | 87.7% | -60.4% | -60.4% | -53.9% | -13.3% | -40.5% | 47.3% | 22.0% | 18.9% | -21.7% |
| ROA | 6.2% | 53.4% | -24.4% | -24.4% | -24.4% | -6.5% | -17.6% | 28.2% | 16.1% | 14.2% | -17.3% |
| Net Profit Margin | 4.9% | 20.2% | -8.3% | -8.3% | -19.9% | -5.1% | -11.3% | 21.0% | 12.2% | 11.6% | -18.5% |
| Debt to Equity | 0.00x | 0.00x | - | 0.00x | 0.57x | 0.58x | 0.70x | 0.34x | 0.13x | 0.09x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
MiMedx Group Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 997K | 0.01 | 1.5% |
| 2022 | USD 651K | 0.01 | - |
| 2021 | USD 1.44M | 0.01 | - |
| 2020 | USD 100M | 0.92 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3235:10000 on Apr 2, 2008.
Who owns MiMedx Group Inc
- Insiders 2.68%
- Institutions 80.80%
- Public & others 16.53%
- Shares outstanding 146M
- Free float 108M
Top funds holding MDXG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.72M | 2.55% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 3.01M | 2.07% | 0.00% | Oct 2026 |
| Avantis US Small Cap Value ETF | 2.15M | 1.48% | +3.62% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.93M | 1.32% | +2.69% | Oct 2026 |
| Fidelity Small Cap Index | 1.32M | 0.90% | 0.00% | Aug 2026 |
| iShares Russell 2000 Value ETF | 1.12M | 0.77% | 0.00% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 837K | 0.57% | +11.98% | Sep 2026 |
| Paradigm Micro-Cap | 800K | 0.55% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 688K | 0.47% | -1.17% | Sep 2026 |
| First Eagle Small Cap Opportunity I | 686K | 0.47% | +33.69% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 609K | 0.42% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 555K | 0.38% | -0.38% | Sep 2026 |
| OP-Osakesalkku A | 423K | 0.29% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 360K | 0.25% | 0.00% | Oct 2026 |
| iShares Micro-Cap ETF | 359K | 0.25% | 0.00% | Oct 2026 |
| Schwab Small-Cap Equity | 358K | 0.25% | -8.88% | Sep 2026 |
| Vanguard Health Care ETF | 348K | 0.24% | +0.11% | Sep 2026 |
| Dimensional US Targeted Value ETF | 310K | 0.21% | 0.00% | Oct 2026 |
| DFA U.S. Targeted Value I | 307K | 0.21% | +14.13% | Sep 2026 |
| DFA U.S. Small Cap I | 292K | 0.20% | +12.31% | Sep 2026 |
Top institutions holding MDXG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Essex Woodlands Health Ventures | 28.2M | 19.32% | 0.00% | Sep 2026 |
| BlackRock Inc | 12.2M | 8.33% | +2.04% | Jun 2026 |
| Nantahala Capital Management, LLC | 9.54M | 6.53% | +180.67% | Jun 2026 |
| Trigran Investments Inc | 7.17M | 4.92% | -0.02% | Jun 2026 |
| State Street Corp | 5.58M | 3.82% | +10.33% | Jun 2026 |
| Vanguard Capital Management, LLC | 5.19M | 3.55% | +0.41% | Jun 2026 |
| Paradigm Capital Management, Inc. | 4.07M | 2.79% | +19.44% | Jun 2026 |
| Geode Capital Management, LLC | 3.14M | 2.15% | +9.11% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.67M | 1.83% | +124.84% | Jun 2026 |
| AQR Capital Management LLC | 2.47M | 1.69% | +170.29% | Jun 2026 |
| Renaissance Technologies Corp | 2.37M | 1.62% | -3.08% | Sep 2026 |
| Punch & Associates Inv Mgmt Inc | 2.06M | 1.41% | +1.90% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.05M | 1.40% | +5.26% | Sep 2026 |
| American Century Companies Inc | 1.90M | 1.30% | +253.10% | Sep 2026 |
| Cannell Capital LLC | 1.87M | 1.28% | +24.93% | Jun 2026 |
| Northern Trust Corp | 1.32M | 0.90% | +28.78% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.29M | 0.88% | +16.71% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 1.27M | 0.87% | +63.25% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.24M | 0.85% | -9.95% | Jun 2026 |
| Meros Investment Management, LP | 1.12M | 0.77% | +2.64% | Jun 2026 |
MiMedx Group Inc company profile
- Company name
- MiMedx Group Inc
- Ticker
- MDXG.US
- Exchange
- USA Stocks
- Listed since
- Aug 22, 2007
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 808
- Fiscal year end
- December
- Address
- 1775 West Oak Commons Court, NE, Marietta, GA, United States, 30062
- Phone
- 770 651 9100
- Website
- mimedx.com
About MiMedx Group Inc
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.
MiMedx Group Inc management
10- Mr. Joseph H. CapperCEO & Director · born 1964
- Mr. Douglas C. Rice CPAChief Financial Officer · born 1966
- Mr. William F. Hulse IVGeneral Counsel & Chief Administrative Officer · born 1974
- Ms. Kimberly Maersk-MollerChief Commercial Officer · born 1967
- Dr. John Harper Ph.D.SVP of R&D & Medical Affairs and Chief Scientific Officer
- Mr. Matthew M. NotarianniHead of Investor Relations
- Mr. Mark P. GravesSenior VP & Chief Compliance Officer · born 1966
- Ms. Hilary DixonVice President of Investor Relations & Corporate Strategic Communications
- Mr. Eric A. SmithSenior VP of Marketing & International · born 1972
- Ms. Tracy ChastainChief Human Resources Officer